Dario Vignali, PhD

    Dario A. A. Vignali, PhD

    Member, St. Jude Faculty
    Vice Chair, Immunology

    Departments

    Immunology

    Contact Information

    Dario A Vignali, PhD
    Immunology
    MS 351, Room E7054
    St. Jude Children's Research Hospital
    262 Danny Thomas Place
    Memphis, TN 38105-3678
    Email: dario.vignali@stjude.org
    Phone: (901) 595-2332
    FAX: (901) 595-3107

    Education

    PhD - London School of Hygiene & Tropical Medicine, University of London
    Postdoctoral position - German Cancer Research Center, Heidelburg, Germany
    Postdoctoral position - Harvard University, Boston, USA


    Honors & Awards


    Research Interests

    Our research focuses on various aspects of T cell function:

    Immune Regulation:

    T cell receptor (TCR):CD3 complex: Molecular initiation and control of TCR signal transduction; role of CD3 in T cell development and function.

    Vignali's Research Group

    Selected Publications

    To request reprints and reagents: vignali.lab@stjude.org

    Out of 129 publications:

    Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DAA*, Ziegler SF. Regulatory T cells: recommendations to simplify the nomenclature. Nature Immunology 2013 (in press). [*Senior author]

    Herold KC, Vignali DAA, Cooke A, Bluestone JA. Type I diabetes: translating mechanistic observations into effective clinical outcomes. Nature Reviews Immunology 2013 (in press). [Invited Review]

    Guy C, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, Zhang H, Huppa JB, Tsai Y-H, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DAA. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nature Immunology 14:262-270, 2013. [Issue Cover] [PMID: 23377202]

    Vignali DAA, Kuchroo VK. IL-12 Family Cytokines: Immunological Playmakers. Nature Immunology 13:722-728, 2012. [PMID: 22814351]

    Turnis ME, Korman AJ, Drake CG, Vignali DAA. Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more. OncoImmunology 1:1172-1174, 2012. [PMID: 23170269; PMCID: 3494635]

    Bettini ML, Pan F, Bettini M, Finkelstein D, Rehg JE, Floess S, Bell BD, Ziegler SF, Huehn J, Pardoll DM, Vignali DAA. Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity 36:717–730, 2012. [Issue Cover] [PMID: 22579476; PMCID: 3361541]

    Bettini M, Castellaw A, Lennon G, Burton AR, Vignali DAA. Prevention of autoimmune diabetes by ectopic pancreatic beta cell expression of Interleukin-35. Diabetes 61:1519-1526, 2012. [PMID: 22427377; PMCID: 3357277]

    Collison LC*, Delgoffe GM*, Guy C, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DAA. The composition and signaling of the IL-35 receptor are unconventional. Nature Immunology 13:290-299, 2012. [PMID: 22306691; PMCID: 3529151]

    Gravano DM, Vignali DAA. The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cellular and Molecular Life Sciences 69:1997-2008. [Invited Review] [PMID: 22205213; PMCID: 3353028]

    Woo S-R*, Turnis ME*, Goldberg MV*, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Vogel P, Liu C-L, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DAA. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Research 72:917-927, 2012. [PMID: 22186141; PMCID: 3288154]

    Bettini M, Szymczak-Workman AL, Forbes K, Castellaw AH, Selby M, Pan X, Drake CG, Korman AJ, Vignali DAA. Cutting Edge: Accelerated autoimmune diabetes in the absence of LAG-3. J Immunol 187:3493-3498, 2011. [PMID: 21873518; PMCID: 3178660]

    Delgoffe GM, Murray PJ, Vignali DAA. Interpreting mixed signals: the cell’s cytokine conundrum. Current Opinion in Immunology 23:632-638, 2011. [Invited Review] [PMID: 21852079; PMCID: 3190023]

    Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni H-T, Artis D, Turk MJ, Vignali DAA. Interleukin-35-mediated induction of a potent regulatory T cell population. Nature Immunology 11:1093-1101, 2010. [PMID: 20953201; PMCID: 3008395]

    Wang H, Holst J, Woo S-R, Guy C, Bettini M, Wang Y, Shafer A, Naramura M, Mingueneau M, Dragone LL, Hayes SM, Malissen B, Band H, Vignali DAA. Tonic ubiquitylation controls T cell receptor:CD3 complex expression during T cell development. EMBOJ 29:1285-1298, 2010. [PMID: 20150895; PMCID: 2857457]

    Lennon GP, Bettini M, Burton AR, Vincent E, Arnold PY, Santamaria P, Vignali DAA. T cell islet accumulation in type I diabetes is a tightly regulated, cell autonomous event. Immunity 31: 643-653, 2009. [PMID:19818656; PMCID: 2763021]

    Collison LW, Pillai MR, Chaturvedi V, Vignali DAA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 182:6121-6128, 2009. [PMID: 19414764; PMCID: 2698997]

    Wang H, Matsuzawa A, Brown S, Zhou J-R, Guy CS, Tseng P-H, Forbes K, Nicholson TP, Sheppard PW, Haecker H, Karin M, Vignali DAA. Analysis of non-degradative protein ubiquitylation with a monoclonal antibody specific for lysine 63-linked polyubiquitin. PNAS 105:20197-20202, 2008. [PMID: 19091944; PMCID: 2629300]

    Holst J, Wang H, Durick Eder K, Workman CJ, Boyd K, Baquet Z, Singh H, Forbes K, Chruscinski A, Smeyne R, van Oers NSC, Utz PJ, Vignali DAA. Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity. Nature Immunology 9:658-666, 2008. [PMID: 18469818 – Accepted March 27, 2008].

    Burton AR, Vincent E, Arnold PY, Lennon, G, Smeltzer M, Li C-S, Haskins K, Hutton J, Tisch RM, Sercarz EE, Santamaria P, Workman CJ, Vignali DAA. On the pathogenicity of autoantigen-specific T cell receptors. Diabetes 57:1321-1330, 2008. [PMID: 18299317]

    Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nature Reviews Immunology 8:523-532, 2008. [PMID: 18566595; PMCID: 2665249]

    Collison LW, Workman CJ, Kuo TK, Boyd K, Wang Y, Vignali K, Cross R, Sehy D, Blumberg RS, Vignali DAA. The inhibitory cytokine IL-35 contributes to regulatory T cell function. Nature 450:566-569, 2007. [PMID: 18033300]

    Li N, Wang Y, Forbes K, Vignali KM, Heale BS, Saftig P, Hartmann D, Black R, Rossi JJ, Blobal C, Dempsey PJ, Workman CJ, Vignali DAA. Metalloproteases regulate T cell proliferation and effector function via LAG-3. EMBOJ 26: 494-504, 2007. [PMID:17245433; PMCID:1783452]

    Holst J, Szymczak-Workman AL, Vignali KM, Burton AR, Workman CJ, Vignali DAA. Generation of T cell receptor retrogenic mice. Nature Protocols 1:406-417. 2006.

    Holst J, Vignali KM, Burton AR, Vignali DAA. Rapid analysis of T cell selection and function in vivo using T cell receptor retrogenic mice. Nature Methods 3:191-197, 2006.

    Workman CJ, Vignali DAA. Negative regulation of T cell homeostasis by LAG-3 (CD223). J Immunol 174:688-695, 2005.

    Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Lavitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DAA. Role of LAG-3 in regulatory T cells. Immunity 21:503-13, 2004. [Issue Cover].

    Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin E, Vignali, DAA. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nature Biotechnology 22:589-594, 2004. [PMID:15064769]

    Workman CJ, Cauley LS, Kim I-J, Blackman M, Woodland DL, Vignali DAA. LAG-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 172:5450-5455, 2004.

    Liu HY, Rhodes M, Wiest D, Vignali DAA. On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. Immunity 13:665-675, 2000. [Issue Cover].

    Carson RT, Vignali KM, Woodland DL, Vignali DAA. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR-V region usage. Immunity 7:387-399, 1997.

    Last update: March 2013